Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Celemics Inc. (331920:KRX), powered by AI.
Celemics Inc. is currently trading at ₩13,000. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Celemics Inc. on Alpha Lenz.
Celemics Inc.'s P/E ratio is 8.7.
“Celemics Inc. trades at a P/E of 8.7 (undervalued) with strong ROE of 57.0%.”
Ask for details →Celemics Inc. is a biotechnology company that specializes in providing next-generation sequencing (NGS) solutions for various research and clinical applications. The company is renowned for its innovative Complete Reagent Solution, which enhances the efficiency and accuracy of genomic sequencing processes. Offering targeted sequencing panels, whole exome sequencing, and whole-genome sequencing, Celemics serves a plethora of industries including healthcare, pharmaceuticals, and academic research institutions. By enabling precise and comprehensive genomic analysis, Celemics plays a pivotal role in advancing personalized medicine, genetic research, and the development of new diagnostics and therapies. Founded with a commitment to quality and innovation, Celemics is instrumental in pushing the boundaries of genetic analysis, ensuring that researchers and clinicians can achieve profound insights into complex biological questions. Through its products and services, the company significantly impacts how genetic data is utilized for medical and scientific advancements.
“Celemics Inc. trades at a P/E of 8.7 (undervalued) with strong ROE of 57.0%.”
Ask for details →Celemics Inc. (ticker: 331920) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 41 employees. Market cap is $106.1B.
The current price is ₩13,000 with a P/E ratio of 8.65x and P/B of 3.9x.
ROE is 56.97% and operating margin is -28.32%. Annual revenue is $6.7B.